{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:24:15Z","timestamp":1762323855469},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,7,29]],"date-time":"2015-07-29T00:00:00Z","timestamp":1438128000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychiatr Q"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s11126-015-9385-z","type":"journal-article","created":{"date-parts":[[2015,7,28]],"date-time":"2015-07-28T16:03:21Z","timestamp":1438099401000},"page":"293-304","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Quality of Life and Hormonal, Biochemical, and Anthropometric Profile Between Olanzapine and Risperidone Users"],"prefix":"10.1007","volume":"87","author":[{"given":"Aurigena Antunes","family":"de Ara\u00fajo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana Barbosa","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Cely Souza","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Telma Maria Ara\u00fajo Moura","family":"Lemos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline Addison Xavier","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerlane Coelho Bernardo","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raimundo Fernandes","family":"de Ara\u00fajo J\u00fanior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoni","family":"Serrano-Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Rubio-Valera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,29]]},"reference":[{"issue":"1","key":"9385_CR1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/15748847113089990057","volume":"9","author":"A Risio De","year":"2014","unstructured":"De Risio A, Lang AP: History and therapeutic rationale of long acting antipsychotics. Current Clinical Pharmacology 9(1):39\u201352, 2014.","journal-title":"Current clinical pharmacology."},{"key":"9385_CR2","unstructured":"Graeff FG, Guimar\u00e3es FS: Medicamentos Antipsic\u00f3ticos. Fundamentos de Psicofarmacologia S\u00e3o Paulo: 1999."},{"issue":"2","key":"9385_CR3","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/070674379704200205","volume":"42","author":"HE Lehmann","year":"1997","unstructured":"Lehmann HE, Ban TA: The history of the psychopharmacology of schizophrenia. Canadian Journal of Psychiatry 42(2):152\u2013162, 1997.","journal-title":"Can J Psychiat."},{"issue":"8","key":"9385_CR4","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3949\/ccjm.74.8.597","volume":"74","author":"M Mathews","year":"2007","unstructured":"Mathews M, Muzina DJ: Atypical antipsychotics: New drugs, new challenges. Cleveland Clinic Journal of Medicine 74(8):597\u2013606, 2007.","journal-title":"Clev Clin J Med."},{"issue":"1","key":"9385_CR5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4002066","volume":"13","author":"HA Nasrallah","year":"2008","unstructured":"Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Molecular Psychiatry 13(1):27\u201335, 2008. doi: 10.1038\/sj.mp.4002066 1.","journal-title":"Molecular psychiatry."},{"issue":"8","key":"9385_CR6","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1017\/S1461145714000157","volume":"17","author":"RM Paredes","year":"2014","unstructured":"Paredes RM, Quinones M, Marballi K, Gao XL, Valdez C, Ahuja SS et al.: Metabolomic profiling of schizophrenia patients at risk for metabolic syndrome. International Journal of Neuropsychopharmacology 17(8):1139\u20131148, 2014. doi: 10.1017\/S1461145714000157 .","journal-title":"Int J Neuropsychoph."},{"issue":"11","key":"9385_CR7","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jaac.2014.08.009","volume":"53","author":"C Arango","year":"2014","unstructured":"Arango C, Giraldez M, Merchan-Naranjo J, Baeza I, Castro-Fornieles J, Alda JA et al.: Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naive patients. Journal of the American Academy of Child and Adolescent Psychiatry 53(11):1179\u20131190, 2014. doi: 10.1016\/j.jaac.2014.08.009 .","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry."},{"issue":"1","key":"9385_CR8","first-page":"86","volume":"40","author":"I Besnard","year":"2014","unstructured":"Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C: Antipsychotic-drug-induced hyperprolactinemia: Physiopathology, clinical features and guidance. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique 40(1):86\u201394, 2014. doi: 10.1016\/j.encep.2012.03.002 .","journal-title":"Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique."},{"issue":"3","key":"9385_CR9","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11126-014-9290-x","volume":"85","author":"AA deAraujo","year":"2014","unstructured":"de Araujo AA, Dantas DD, do Nascimento GG, Ribeiro SB, Chaves KM, Silva VD, et al.: Quality of life in patients with schizophrenia: The impact of socio-economic factors and adverse effects of atypical antipsychotics drugs. Psychiatric Quarterly 85(3):357\u2013367, 2014. doi: 10.1007\/s11126-014-9290-x .","journal-title":"Psychiatric Quarterly"},{"issue":"1","key":"9385_CR10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11126-012-9233-3","volume":"84","author":"KM Chaves","year":"2013","unstructured":"Chaves KM, Serrano-Blanco A, Ribeiro SB, Soares LA, Guerra GC, do Socorro Costa Feitosa Alves M, et al.: Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia. The Psychiatric Quarterly 84(1):125\u2013135, 2013. doi: 10.1007\/s11126-012-9233-3 .","journal-title":"The Psychiatric Quarterly"},{"key":"9385_CR11","unstructured":"Manual Diagn\u00f3stico e Estat\u00edstico de Transtornos Mentais\u2014DSM-IV-TR-TM. ArtMed Porto Alegre, 2003."},{"issue":"9251","key":"9385_CR12","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0140-6736(05)71342-8","volume":"357","author":"D Human","year":"2001","unstructured":"Human D: Declaration of Helsinki. Lancet 357(9251):236, 2001. doi: 10.1016\/S0140-6736(05)71342-8 .","journal-title":"Lancet."},{"issue":"1","key":"9385_CR13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/07315724.1993.10718275","volume":"12","author":"FA Kummerow","year":"1993","unstructured":"Kummerow FA: Viewpoint on the Report of the National Cholesterol Education Program Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Journal of the American College of Nutrition 12(1):2\u201313, 1993.","journal-title":"Journal of the American College of Nutrition."},{"key":"9385_CR14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1590\/S0066-782X2007000700002","volume":"88","author":"AC Sposito","year":"2007","unstructured":"Sposito AC, Caramelli B, Fonseca FAH, Bertolami MC, Afiune Neto A, Souza AD, et al.: IV Diretriz Brasileira sobre Dislipidemias e Preven\u00e7\u00e3o da Aterosclerose: Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. Arquivos Brasileiros de Cardiologia 88:2\u201319, 2007.","journal-title":"Arquivos Brasileiros de Cardiologia."},{"key":"9385_CR15","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1590\/S0004-282X2011000300010","volume":"69","author":"EB Pinto","year":"2011","unstructured":"Pinto EB, Maso I, Vilela RNR, Santos LC, Oliveira-Filho J: Validation of the EuroQol quality of life questionnaire on stroke victims. Arquivos de Neuro-Psiquiatria 69:320\u2013323, 2011.","journal-title":"Arquivos de neuro-psiquiatria."},{"key":"9385_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","volume":"334","author":"O Lingjaerde","year":"1987","unstructured":"Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K: The UKU side effect rating scale A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica Supplementum 334:1\u2013100, 1987.","journal-title":"Acta psychiatrica Scandinavica Supplementum"},{"issue":"1","key":"9385_CR17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2377-5-5","volume":"5","author":"S Janno","year":"2005","unstructured":"Janno S, Holi MM, Tuisku K, Wahlbeck K. Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population. BMC Neurology 5(1):5, 2005, doi: 10.1186\/1471-2377-5-5 .","journal-title":"BMC neurology."},{"issue":"6","key":"9385_CR18","first-page":"357","volume":"25","author":"MR LouzaNeto","year":"1998","unstructured":"Louza Neto MR: Escalas de avaliacao de efeitos colaterais de antipsicoticos; Rating scales of side effects of antipsychotics. Rev Psiquiatr Cl\u00edn 25(6):357\u2013367, 1998.","journal-title":"Rev psiquiatr cl\u00edn"},{"key":"9385_CR19","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1590\/S1413-81232013000200029","volume":"18","author":"FC Valadares","year":"2013","unstructured":"Valadares FC: Desafios pol\u00edticos da reforma psiqui\u00e1trica brasileira. Ciencia & Saude Coletiva 18:573\u2013574, 2013.","journal-title":"Ciencia & saude coletiva."},{"key":"9385_CR20","doi-asserted-by":"crossref","unstructured":"Costa JAS, Andrade KVFD: Perfil dos usu\u00e1rios inclu\u00eddos no protocolo de esquizofrenia em um programa de medicamentos do componente especializado da assist\u00eancia farmac\u00eautica Profile of patients included in the protocol of schizophrenia in a drug program from specialized component of pharmaceutical assistance Perfil de los usuarios incluidos en el protocolo de esquizofrenia en um programa de medicinas del componente especializado de la asistencia farmac\u00e9utica. Rev Baiana Sa\u00fade P\u00fablica 35(2), 2011.","DOI":"10.22278\/2318-2660.2011.v35.n2.a317"},{"key":"9385_CR21","unstructured":"Sa\u00fade Md. PORTARIA N\u00b0 364, DE 9 DE ABRIL DE 2013: Aprova o Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas - Esquizofrenia. In: Sa\u00fade SdA\u00e0, editor. Bras\u00edlia 2013."},{"key":"9385_CR22","first-page":"3","volume":"84","author":"I Diretriz","year":"2005","unstructured":"Diretriz I: Brasileira de Diagn\u00f3stico e Tratamento da S\u00edndrome Metab\u00f3lica. Arquivos Brasileiros de Cardiologia 84:3\u201328, 2005.","journal-title":"Arquivos Brasileiros de Cardiologia."},{"issue":"1","key":"9385_CR23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/2045125313507738","volume":"4","author":"M Salviatobalbao","year":"2014","unstructured":"Salviato Balbao M, Cecilio Hallak JE, Arcoverde Nunes E, Homem de Mello M, Triffoni-Melo Ade T, Ferreira FI, et al.: Olanzapine, weight change and metabolic effects: A naturalistic 12-month follow up. Therapeutic Advances in Psychopharmacology 4(1):30\u201336, 2014, doi: 10.1177\/2045125313507738 .","journal-title":"Therapeutic Advances in Psychopharmacology"},{"issue":"5","key":"9385_CR24","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1017\/S1461145712001241","volume":"16","author":"WW Fleischhacker","year":"2013","unstructured":"Fleischhacker WW, Siu CO, Boden R, Pappadopulos E, Karayal ON, Kahn RS. Metabolic risk factors in first-episode schizophrenia: Baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. International Journal of Neuropsychopharmacology 16(5):987\u2013995, 2013 doi: 10.1017\/S1461145712001241 .","journal-title":"Int J Neuropsychopharmacol."},{"key":"9385_CR25","doi-asserted-by":"crossref","first-page":"307202","DOI":"10.1155\/2014\/307202","volume":"2014","author":"S Shoja Shafti","year":"2014","unstructured":"Shoja Shafti S, Gilanipoor MA: Comparative Study between ola1nzapine and risperidone in the management of schizophrenia. Schizophrenia Research and Treatment 2014:307202, 2014. doi: 10.1155\/2014\/307202 .","journal-title":"Schizophrenia Research and Treatment"}],"container-title":["Psychiatric Quarterly"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11126-015-9385-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11126-015-9385-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11126-015-9385-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T09:44:00Z","timestamp":1652953440000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11126-015-9385-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,29]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["9385"],"URL":"https:\/\/doi.org\/10.1007\/s11126-015-9385-z","relation":{},"ISSN":["0033-2720","1573-6709"],"issn-type":[{"value":"0033-2720","type":"print"},{"value":"1573-6709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,29]]}}}